National production of L-asparaginase from Streptomyces caatingaensis CMAA1322

• Grant number: 17/08244-7
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: February 01, 2018
• End date: February 28, 2019
• Field of knowledge: Biological Sciences - Microbiology - Applied Microbiology
• Principal Investigator: Suikinai Nobre Santos
• Grantee: Suikinai Nobre Santos
• Company: Biodiversita Serviços de Apoio Agrícola Ltda. - ME
• CNAE: Fabricação de medicamentos para uso humano
• City: Jaguariúna
• Pesquisadores principais: Diego Bonaldo Genuário
• Associated researchers: Leonardo José da Silva ; Wallance Moreira Pazin
• Associated scholarship(s): 18/00404-8 - National production of L-asparaginase from Streptomyces caatingaensis CMAA1322, BP.PIPE

Abstract

Currently, there is a high global demand in the search for alternatives for the production of active principles by biotechnological processes. As in the research, the industrial production of drugs in Brazil presents weak expression in the world scenario. Also, international suppliers of biopharmaceuticals are losing interest in the Brazilian market and discontinuing the production of several of these, especially those related to the treatment of onco-hematological diseases. The present project aims at the decay of stable L-Asparaginases enzymes from fermented broths of bacterial isolates, using the Streptomyces caatingaesnsis strain CMAA1322, a new and genuinely Brazilian isolate of the caatinga biome, in previous studies, by associated biotechnological processes The scientific and technological competencies established by Brazilian research groups and using national genetic and biological resources. The resultant ASPases biopharmaceutical will be a product of strategic innovation with a national and international market target, based on bacterial biopharmaceuticals, not observed by any national company so far. In previous screenings the potential of the bacterial strain CMAA1322 in the production of L-Asparaginase in vitro, as well as studies of the gene groups responsible for its biosynthesis were detected. In this context, in the initial phase, the strategies will be orchestrated in three different fronts, using as scaffold the L-Asparaginase of S. caatingaensis CMAA1322 Platform I (Evaluation of the potential of extracellular production in liquid medium, and optimization of production at laboratory level); Platform II (Pre-purification and enzymatic purification of extracts and fractions); Platform III (Monitoring the anticancer activity of enzymes and toxicity obtained on platforms I and II). At the end of this period, the objective was to confirm the viability of the technology developed using this strain in the production of L-Asparaginase. It is intended to create conditions for the development of processes and production of asparaginases with quality in laboratory scale using simple, cheap and safe methods. It is hoped to obtain promising results from the point of view of technology transfer to industry and that are in line with the national demand for this biopharmaceutical for the treatment of cancer. (AU)